Methylhydroxynandrolone
| Clinical data | |
|---|---|
| Routes of administration | Oral[1] |
| Identifiers | |
| |
| Synonyms | MOHN; MHN; 4-Hydroxy-17α-methyl-19-nortestosterone; 4,17β-Dihydroxy-17α-methylestr-4-en-3-one |
| CAS Number | 2747-16-2 |
| PubChem (CID) | 351707 |
| ChemSpider | 312271 |
| Chemical and physical data | |
| Formula | C19H28O3 |
| Molar mass | 304.43 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
Methylhydroxynandrolone (MOHN, MHN), also known as 4-hydroxy-17α-methyl-19-nortestosterone, as well as 4,17β-dihydroxy-17α-methylestr-4-en-3-one, is a synthetic, orally active anabolic-androgenic steroid (AAS) and a 17α-alkylated derivative of 19-nortestosterone (nandrolone) that was never marketed.[1] It was first described in 1964, but was not developed for clinical use.[1] The drug re-emerged in 2004 when it started being sold on the Internet without a prescription as a "dietary supplement".[1] MOHN joined other AAS as a controlled substance in the United States on 20 January 2005.[1]
MOHN is non-aromatizable due to the presence of a hydroxy group at the C4 position, and for this reason, poses no risk of estrogenic side effects like gynecomastia at any dosage.[1] 5α-Reduction is also inhibited by the C4 hydroxy group of MOHN, and because of this, it may be relatively more androgenic than other nandrolone derivatives (as 5α-reduction decreases AAS potency in these drugs).[1] Early assays found that MOHN had approximately 13 times the anabolic activity and 3 times the androgenic activity of methyltestosterone.[1]
MOHN is the 4-hydroxylated derivative of normethandrone (17α-methyl-19-nortestosterone), the 17α-methylated derivative of oxabolone (4-hydroxy-19-nortestosterone), the 4-hydroxylated and 17α-methylated derivative of nandrolone (19-nortestosterone), and the non-19-demethylated analogue of oxymesterone (4-hydroxy-17α-methyltestosterone).[1]